No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 8.1700
- -1.3100-13.82%
Close Jul 19 16:00 ET
- 8.2000
- +0.0300+0.37%
Post 19:58 ET
169.58MMarket Cap-800P/E (TTM)
9.9471High8.0000Low558.34KVolume9.7700Open9.4800Pre Close4.78MTurnover5.26%Turnover RatioLossP/E (Static)20.76MShares29.700052wk High0.93P/B86.68MFloat Cap6.380052wk Low--Dividend TTM10.61MShs Float624.8000Historical High--Div YieldTTM20.54%Amplitude5.3100Historical Low8.5660Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the
Express News | Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((Reverse Stock Split 1:10))
Adverum Biotechnologies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/18/2024 322.83% Chardan Capital $4 → $40 Maintains Buy 06/25/2024 164.27% Oppenheimer → $25 Initiates
Chardan Research Adjusts Adverum Biotechnologies' PT to $40 From $4, Maintains Buy Rating
Adverum Biotechnologies (ADVM) has an average rating of buy and price targets ranging from $15 to $60, according to analysts by Capital IQ.Price: 8.10, Change: -0.68, Percent Change: -7.74
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $23
Truist Financial analyst Joon Lee maintains $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 52.8%
Adverum Biotechnologies' Promising AMD Treatment Advances
Comments
$Adverum Biotechnologies(ADVM.US$
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
2
$Adverum Biotechnologies(ADVM.US$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
1
2
$Adverum Biotechnologies(ADVM.US$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
1
1
Let’s see.
$Adverum Biotechnologies(ADVM.US$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg